Wall Street Zen Downgrades Puma Biotechnology to Hold

Analysts cite concerns over the company's lead product, neratinib, in a new research report.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Puma Biotechnology (NASDAQ:PBYI) was downgraded by equity research firm Wall Street Zen from a 'buy' rating to a 'hold' rating in a report issued on Saturday. Separately, Weiss Ratings also reiterated a 'hold (c+)' rating on Puma Biotechnology's shares. The downgrade comes as the biopharmaceutical company prepares to report its latest quarterly earnings results.

Why it matters

Puma Biotechnology's lead product, neratinib, is an important cancer treatment that received FDA approval in 2017 for extended adjuvant treatment of early-stage HER2-positive breast cancer. The downgrade by Wall Street Zen could signal concerns about the drug's commercial performance and future prospects, which would impact the company's financial outlook.

The details

In the report, Wall Street Zen analysts cited unspecified factors in downgrading Puma Biotechnology from a 'buy' to a 'hold' rating. Separately, Weiss Ratings maintained its 'hold (c+)' rating on the company's shares. Puma Biotechnology is scheduled to report its latest quarterly earnings results on Thursday, February 26th.

  • Puma Biotechnology was downgraded by Wall Street Zen on Saturday, February 29, 2026.
  • Weiss Ratings reiterated its 'hold (c+)' rating on Puma Biotechnology on Thursday, January 22, 2026.
  • Puma Biotechnology is scheduled to report its Q4 2025 earnings results on Thursday, February 26, 2026.

The players

Wall Street Zen

An equity research firm that provides analysis and ratings on publicly traded companies.

Weiss Ratings

An independent financial ratings agency that provides research and analysis on stocks, mutual funds, and other financial products.

Puma Biotechnology, Inc.

A late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for oncology patients, with a lead product called neratinib that is approved for extended adjuvant treatment of early-stage HER2-positive breast cancer.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Puma Biotechnology's upcoming Q4 2025 earnings report on February 26, 2026 for any updates on the commercial performance of neratinib and the company's overall financial outlook.

The takeaway

The downgrade of Puma Biotechnology by Wall Street Zen raises concerns about the future prospects of the company's lead cancer drug neratinib, which could impact the stock's performance going forward. Investors will be closely monitoring the company's upcoming earnings report for more clarity on the drug's commercial trajectory.